Author: admin

Austin card shows gain popularity in June 2026 as the trading card hobby grows

The trading card hobby continues to grow in 2026, with PSA grading over two million cards in May and Pokémon products selling out in stores. Card Groove lists eight Austin card shows in June, reflecting the trend.

The trading card hobby continued to grow through the first half of 2026, with rising card grading volume, sustained demand for Pokémon products, and a busy schedule of local events. The trend is visible in Austin, Texas, where eight card shows are scheduled across the metro area in June, alongside a growing number of recurring weekly gatherings. Card Groove, an online directory of local trading card shows, compiled the schedule and tracks similar activity across the markets it covers.

The scale of collector demand is reflected in recent grading figures. According to data published by GemRate, PSA graded about 2.07 million cards in May 2026, an increase of roughly 25 percent year over year, while the industry graded close to 2.95 million cards across all companies. Demand has grown to the point that PSA has temporarily paused new submissions for its four lowest-cost Value tiers, effective June 2, 2026, citing a backlog of nearly 10 million cards. Trading card games (TCGs) such as Pokémon, One Piece, and Magic: The Gathering have surged in popularity, and the rise in TCG submissions has contributed to this growth.

Demand has been especially visible in the Pokemon market, where new products have been difficult to find on store shelves. Retailers have reported selling out quickly, and collectors have formed lines ahead of store openings when restocks are expected. The shortage has pushed many collectors toward in-person card shows as an alternative source for both sealed product and single cards.

Card shows provide a setting where collectors can buy, sell, and trade in person. The following card shows are scheduled in the Austin metro area in June 2026:

  • Legacy Card Show — June 6 at the Courtyard by Marriott, Austin. Free admission.

  • Mom and Pop Card Show, South Austin — June 7 at Ants Beer Cave, Austin. Five-dollar admission.

  • Austin Card Show — June 12 to 14 at the Palmer Events Center, Austin. A three-day show with more than 400 tables; ten-dollar admission.

  • Bat City Card Show — June 13 at Kenny’s Collectibles, Austin. Free admission.

  • Mom and Pop Card Show, Cedar Park — June 14 at The Fieldhouse at The Crossover, Leander. Five-dollar admission.

  • Home Town Card Show — June 20 at Red Horn Coffee and Brewery, Leander. Free admission, with more than 20 tables.

  • Home Town Card Show — June 21 at VFW Post 8787, Austin. Free admission, with more than 50 tables.

  • ATX Card Show — June 27 and 28 at the Hilton Austin, Austin. A two-day show with more than 300 tables; ten-dollar admission.

Recurring weekly events have also expanded. Craigo’s Card Show, hosted by Lakeway Card Show, runs every Tuesday at Craigo’s Sunset Valley in South Austin and every Thursday at Craigo’s Pizza & Pastaria in Lakeway, both from 2 p.m. to 8 p.m. with free admission, covering Pokémon, One Piece, and sports cards. Local card shops have added regular trade nights as well, including Card Gurus Comics and Collectibles in Pflugerville and a weekly Saturday trade night from 1 p.m. to 6 p.m. at Card Traders of Austin on Spicewood Springs Road. These recurring sessions give collectors midweek and weekend options between the larger monthly shows.

Attendees at Austin shows typically find vintage and modern cards, singles, sealed products, and professionally graded cards, with most shows featuring dedicated Pokémon tables alongside sports card vendors.

“Interest in the hobby has grown steadily this year, and that is showing up in how many shows are running locally,” said Kevin Jones of Card Groove. “When products are hard to find in stores, shows give collectors a place to buy, sell, and trade in person.”

Media Contact
Company Name: Card Groove
Contact Person: Kevin Jones
Email: Send Email
Phone: (512) 920-3295
City: Austin
State: Texas
Country: United States
Website: https://cardgroove.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Austin card shows gain popularity in June 2026 as the trading card hobby grows

45 Years of Hilton’s: Founder Shawn Hilton Marks Nearly Half a Century Protecting Carlisle and Central PA Businesses

From a 1965 Dodge van and a teenage locksmith in 1981 to a modern electronic security firm serving commercial and residential clients across Central Pennsylvania, Hilton’s Electronic Security celebrates a 45-year milestone.

Hilton’s Electronic Security, the Carlisle-based commercial and residential security provider, is marking 45 years in business in 2026. Founded in November 1981 by Shawn Hilton at the age of 17, the company has grown from a one-person locksmithing operation into one of Central Pennsylvania’s longest-standing electronic security firms, serving businesses, schools, healthcare facilities, government buildings, and homeowners across the region.

In its earliest days, the company operated out of a robin-egg blue 1965 Dodge van with hand-stenciled red and yellow lettering, a vehicle that became a familiar sight on Carlisle streets. Shawn Hilton spent those first years driving the van around Cumberland County offering rekeying, master keying, key cutting, emergency lockouts, and deadbolt installations, building a reputation one customer at a time.

“I was 17 years old with a van, a set of tools, and a phone number painted on the side,” said Shawn Hilton, founder of Hilton’s Electronic Security. “I had no big business plan. I just had the belief that if I showed up on time, did the work right, and treated people fairly, the rest would follow. Forty-five years later, that is still the way we run this place.”

As customer needs evolved over the decades, the business evolved with them. Electronic access control, surveillance cameras, alarm systems, intercoms, and structured cabling were added to the lineup, allowing Hilton’s to serve larger and more complex projects across Carlisle, Mechanicsburg, Camp Hill, Boiling Springs, and the wider Harrisburg region. The company quietly grew to become a trusted security partner for some of the area’s most security-sensitive environments.

In 2024, after more than four decades of locksmithing alongside electronic security work, the company made a defining decision. It would transition away from locksmithing entirely and focus solely on modern electronic security solutions. The rebrand to Hilton’s Electronic Security reflects that focus, backed by more than 40 years of trade experience and deep relationships across Central PA.

Today, Hilton’s Electronic Security designs and installs commercial-grade systems for clients across government, healthcare, education, retail, food service, and manufacturing and logistics. Services include access control systems, commercial video surveillance, intercom systems, commercial alarm systems, network installation and cabling, and point-to-point wireless solutions. Residential clients are also supported with home alarm systems and surveillance. To date, the company has completed more than 6,000 projects across the region.

“The technology has changed completely since 1981. The tools, the systems, the threats are all different,” Hilton added. “What has not changed is how we treat our customers. We still answer the phone, we still show up, and we still make sure the system works the way it is supposed to work. That is the part we will never modernize away from.”

Carlisle and Central PA businesses, schools, healthcare facilities, government agencies, and homeowners interested in upgrading their security systems can request a consultation at any time. Hilton’s Electronic Security offers free site assessments and a 24/7 service line.

To learn more or request a quote, visit https://hiltonsls.com or call Hilton’s Electronic Security at 717-243-9475.

About Hilton’s Electronic Security

Founded in 1981 by Shawn Hilton in Carlisle, Pennsylvania, Hilton’s Electronic Security is one of Central PA’s longest-running security service providers, with more than four decades of experience protecting businesses, schools, healthcare facilities, government buildings, and homeowners. Originally established as a locksmithing service, the company rebranded in 2024 to focus exclusively on electronic security solutions, including access control, video surveillance, intercoms, alarm systems, network installation and cabling, and point-to-point wireless. Hilton’s Electronic Security serves clients across Carlisle, Mechanicsburg, Camp Hill, Boiling Springs, Harrisburg, and the wider Central PA region.

Learn more at https://hiltonsls.com.

Media Contact
Company Name: Hilton’s Electronic Security
Contact Person: Shawn Hilton
Email: Send Email
Phone: +17172439475
Address:1787 W Trindle Rd #801
City: Carlisle
State: Pennsylvania (PA) 17015
Country: United States
Website: https://hiltonsls.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: 45 Years of Hilton’s: Founder Shawn Hilton Marks Nearly Half a Century Protecting Carlisle and Central PA Businesses

O’Neill’s Green Solar Launches in Livermore, CA – Licensed Bay Area Solar Installer Now Serving Livermore & Pleasanton Homeowners

Mike O’Neill opens O’Neill’s Green Solar in Livermore, CA — a licensed solar installation company (CA Lic. #1059264) serving Livermore, Pleasanton and the Bay Area. The company also offers pavers and turf through sister brand O’Neill’s Green Services

LIVERMORE, Calif. – June 5, 2026 – Mike O’Neill has officially launched O’Neill’s Green Solar, a licensed solar installation company headquartered in Livermore, Calif., bringing clean energy contracting services to homeowners and businesses throughout the Bay Area.

Operating from 6776 Patterson Pass Rd, Livermore, CA 94550, O’Neill’s Green Solar holds California Contractor’s License No. 1059264. The company provides professional solar panel installation designed to reduce energy costs and lessen dependence on the utility grid. Primary service areas include Livermore, Pleasanton, and surrounding Bay Area communities.

O’Neill brings a strong foundation in outdoor property improvement to this new venture. His established company, O’Neill’s Green Services (ogservices.us), has served Livermore-area clients with quality pavers and turf installation projects. The combined portfolio of services allows property owners to address both exterior landscaping and renewable energy needs through a trusted local contractor.

“Our goal is to make solar accessible and straightforward for Bay Area homeowners,” O’Neill said. “We bring the same quality and reliability to solar installation that our clients have come to expect from our landscaping and outdoor services.”

As energy costs continue to rise across California, local contractors with clean energy expertise are increasingly important to residential and commercial property owners in the Tri-Valley region. O’Neill’s Green Solar meets this demand with hands-on, locally focused service.

For solar installation inquiries in Livermore, Pleasanton or the greater Bay Area, contact O’Neill’s Green Solar at (925) 443-7888 or visit https://ogsolar.us/

​

Media Contact
Company Name: O’Neill’s Green Solar
Contact Person: 6776 Patterson Pass Rd
Email: Send Email
Phone: (925) 443-7888
City: Livermore
State: CA
Country: United States
Website: https://ogsolar.us/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: O’Neill’s Green Solar Launches in Livermore, CA – Licensed Bay Area Solar Installer Now Serving Livermore & Pleasanton Homeowners

William K. Dorrance’s Encounters With God Inspires Readers Through Powerful Stories of Faith, Hope, and Divine Presence

Encounters With God by William K. Dorrance is an inspiring collection of spiritual reflections and real-life experiences that explores faith, hope, and divine presence in everyday life. Praised for its clarity and heartfelt storytelling, the book encourages readers to discover meaning, purpose, and spiritual connection. Its uplifting message and emotionally compelling narratives make it both a must-read and a strong candidate for film adaptation.

William K. Dorrance’s Encounters With God Inspires Readers Through Extraordinary Stories of Faith, Divine Presence, and Spiritual Discovery. In a world often filled with uncertainty, skepticism, and distraction, William K. Dorrance’s Encounters With God offers readers a powerful reminder that the sacred can still be found in everyday life. This inspiring collection of spiritual experiences and reflections stands apart from many books in its genre by presenting profound encounters with faith, divine intervention, and personal transformation through a remarkably accessible and authentic voice. Praised by critics for its clarity and insight, the book has garnered recognition from respected review publications, including US Review of Books, which noted that Dorrance tackles incredibly complex spiritual topics with a pure and simplified lens, making them understandable to readers from all walks of life. Likewise, Pacific Book Review describes the work as a moving collection that offers inspiration for anyone who has ever longed for a glimpse of the sacred in everyday life.

What makes Encounters With God particularly unique is its ability to bridge the gap between spiritual mystery and practical understanding. Rather than presenting faith as an abstract concept, Dorrance shares personal experiences and observations that allow readers to reflect on their own spiritual journeys and the possibility of divine presence in their lives. The author’s sincerity, humility, and gift for storytelling create a deeply engaging reading experience that resonates with believers, seekers, and anyone curious about life’s deeper questions. Through stories that explore faith, hope, purpose, miracles, and personal revelation, the book encourages readers to look beyond the surface of everyday existence and recognize the extraordinary moments that often go unnoticed.

Beyond its literary value, Encounters With God possesses significant potential for adaptation into film or a faith based streaming series. The book’s emotionally compelling accounts, inspirational themes, and exploration of human spirituality provide rich material for cinematic storytelling. Modern audiences continue to embrace films that offer hope, redemption, and meaningful reflections on faith, and Dorrance’s work delivers all of these elements with authenticity and heart. The collection’s vivid narratives, emotional depth, and universal message about the search for meaning could translate beautifully to the screen, creating a powerful viewing experience capable of inspiring audiences around the world. As interest in uplifting and spiritually driven content continues to grow, Encounters With God stands as both a must-read book and a compelling candidate for film adaptation, offering a timeless message that transcends generations and reminds readers that the divine may be closer than they think.

For more information about Encounters With God by William K. Dorrance, including book details, author information, reviews, and updates, visit:

https://williamkdorrance.com/

Book information is also available at:

https://h1.nu/1w8cg

Media Contact
Company Name: Readers Quill Agency
Contact Person: Travis Jackson
Email: Send Email
Phone: 3073161175
Address:1603 Capitol Ave Ste 415 #382469
City: Cheyenne
State: WY
Country: United States
Website: https://readersquillagency.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: William K. Dorrance’s Encounters With God Inspires Readers Through Powerful Stories of Faith, Hope, and Divine Presence

Is There a TikTok for Hiring Local Workers? GigNGo’s GigFeed Is Exactly That

TikTok changed how people discover and trust strangers online. GigNGo’s GigFeed applies that same short-form video mechanic to local hiring — letting homeowners scroll through workers, see their personality and skills, and hire someone they already feel like they know.

GRAND RAPIDS, MI – May 30, 2026 – When TikTok introduced the world to short-form video discovery, it changed something fundamental about how people find things they trust. You didn’t search for a creator. You scrolled until one found you — and when they did, you already felt like you knew them before you ever clicked follow.

That same dynamic — scroll, discover, trust — has never existed in local hiring. Until now.

GigNGo’s GigFeed is the first short-form video discovery feed built specifically for local services. It works exactly the way the question suggests: a homeowner opens the app, scrolls through short videos posted by local workers, and hires the one they feel like they already know. No anonymous profiles. No star ratings sorted by price. Just real people showing real work in real time.

The parallel to TikTok is intentional — and precise. TikTok proved that the best way to build trust with a stranger is to let them watch you before they commit to anything. GigNGo applies that exact mechanic to the moment a homeowner decides who is coming into their house.

A plumber who explains what he is fixing while he fixes it. A house cleaner who shows the before and after of every job. A landscaper who documents a full yard transformation in sixty seconds. These are not advertisements. They are proof — visible, scrollable, trustworthy proof that lives on a Google-indexed profile and compounds in value every time a new video is posted.

“We looked at what TikTok did for creators and asked why that didn’t exist for workers,” said Cameron Lockrey, Founder of GigNGo. “A tradesperson with great skills and a great personality should be able to show that — not just list it. The GigFeed is how that happens.”

For workers, the GigFeed is more than a discovery tool. It is a personal brand engine. Every video posted on GigNGo builds a worker’s visible professional identity — indexed by Google, discoverable beyond the app, and owned entirely by the worker. Unlike followers on TikTok or Instagram that belong to the platform, a GigNGo profile is a permanent professional asset.

And unlike every social platform a worker might already use to promote their services, GigNGo connects discovery directly to hiring. A homeowner who likes what they see can message, book, and pay — all inside the same experience.

GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces. The platform is commission-free — workers pay a flat monthly subscription and keep 100% of their earnings — meaning the incentive to post great content is direct and immediate. Better content means more visibility. More visibility means more work. More work means more income the platform never touches.

For anyone who has wondered whether there is a TikTok for hiring local workers — GigNGo is exactly that. And it is already live.

Workers and homeowners can join GigNGo today at gigngo.org or by downloading the app on iOS and Android.

About GigNGo

GigNGo (gigngo.org) is a workers-first local services marketplace founded by Cameron Lockrey. The platform allows workers to keep 100% of their earnings through a flat monthly subscription, while employers post jobs for free. GigNGo’s GigFeed — a TikTok-style short-form video discovery feed — lets workers build personal brands so their character gets them the job. GigNGo has surpassed thousands of users with active posts spanning all 50 U.S. states and multiple Canadian provinces.

Media Contact
Company Name: GigNGo
Contact Person: Cameron Lockrey
Email: Send Email
Phone: 5304339682
Address:2951 Englewood Ave
City: Grand Rapids
State: MI
Country: United States
Website: https://gigngo.org

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Is There a TikTok for Hiring Local Workers? GigNGo’s GigFeed Is Exactly That

NHU Receives Multiple Honors at the Launch Ceremony of Shaoxing’s 2026 Love Enterprise Action Campaign

On May 27, the launch ceremony of Shaoxing’s 2026 Love Enterprise Action campaign was grandly held under the theme of Supporting Enterprises with Care, Empowering the Future with Intelligence. At the event, NHU was proud to receive three distinguished awards: Top 100 Private Enterprises in Shaoxing 2026, Top 10 Enterprises by R&D Investment in Shaoxing 2026, and Top 10 Foreign Trade Exporters in Shaoxing 2026. Ms. Zhang Liying, Vice President of the Company, attended the ceremony and accepted the awards on behalf of NHU. These recognitions reflect the strong endorsement of NHU’s overall strength, innovation capabilities, and global competitiveness by the Shaoxing Municipal Party Committee, the Municipal Government, and the wider community. They also underscore NHU’s role as a benchmark enterprise and a key contributor to regional economic development.

Guided by our mission of “Chemistry for a Better Life,” NHU has consistently placed innovation at the core of our development strategy. By closely monitoring societal needs, continuously increasing R&D investment, and expanding our scientific talent pool, we remain focused on national strategies and industrial upgrading — tackling key technologies and accelerating the development and commercialization of new products and processes. Being named among the Top 10 Enterprises by R&D Investment in Shaoxing 2026 is a strong testament to NHU’s long-term commitment to innovation-driven growth. We firmly believe that only by upgrading products through innovation and meeting and leading market demand with high-quality offerings can we achieve sustained success in a competitive marketplace, and harness the power of chemistry to create a better life for humanity.

Building on this solid foundation of innovation, we are also advancing our global development strategy. In pursuit of our strategic vision of “NHU in China, NHU to the World,” we are deepening our integration into the global industrial ecosystem and advancing internationalization across R&D, sales, talent, and management. Through a growing global network of R&D resources and sales capabilities, NHU serves customers across the world while continuously enhancing brand influence and international competitiveness. Looking ahead, we will further strengthen our global presence, bringing more high-quality products to customers worldwide and making the NHU name resonate in every corner of the globe.

These honors recognize NHU’s achievements to date while inspiring the company’s future endeavors. Taking them as a new starting point, we will remain committed to our dual engines of innovation and globalization, contributing to industry advancement, and supporting the high-quality development of China’s economy.

Media Contact
Company Name: Lingrong Culture
Contact Person: Wang Yurong
Email: Send Email
Phone: 2134007851
Address:3185 Wilshire blvd
City: Los Angeles
State: CA
Country: United States
Website: www.lingrongculture.com

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: NHU Receives Multiple Honors at the Launch Ceremony of Shaoxing’s 2026 Love Enterprise Action Campaign

Women-Owned Optical Practice: Noelle Calzone and Michele Henry Mark a New Era at Mechanicsburg’s Hampden Optical

Two veteran board-certified opticians with more than 45 years of combined experience continue the legacy of Central Pennsylvania’s longest-standing independent eye care destination, established in 1996.

Hampden Optical, the trusted independent eye care and designer eyewear destination on the Carlisle Pike in Mechanicsburg PA, is entering a new chapter under the leadership of co-owners Noelle Calzone and Michele Henry. Both board-certified opticians acquired the practice in 2024 and continue to build on its nearly three-decade legacy of personalized vision care in Central Pennsylvania.

Founded in 1996, Hampden Optical has spent more than 25 years providing the Mechanicsburg, Harrisburg, Carlisle, and surrounding Central PA communities with comprehensive eye exams, designer eyewear, and a level of one-on-one service that independent practices are uniquely positioned to offer. With Calzone and Henry at the helm, that tradition continues alongside a renewed focus on style, technology, and a fun, welcoming patient experience.

Calzone brings more than 25 years of optical experience to her role as co-owner and board-certified optician. Known for her precision with difficult prescriptions, adjustments, and repairs, she has built a loyal following of patients across Central PA who rely on her depth of knowledge and her steady hands.

“Eye care is personal,” said Noelle Calzone, co-owner of Hampden Optical. “We get to know our patients, their lifestyles, and what they actually need from their eyewear. That kind of attention is something only an independent practice can deliver, and it is what we are committed to protecting and growing.”

Henry brings more than 20 years of optical experience and a reputation as the practice’s “fixer of all things,” with particular strength in frame adjustments and repairs. Her sense of style and warm personality have helped redefine what choosing eyewear can feel like.

“Picking out glasses should be fun, not stressful,” said Michele Henry, co-owner of Hampden Optical. “We want every person who walks through our doors to leave feeling confident in how they look and how they see. That is the whole experience we have built here.”

Alongside Calzone and Henry, the Hampden Optical team includes Dr. David E. Paden, OD, a Pennsylvania College of Optometry graduate who completed a residency in ocular disease and refractive eye care at OMNI Eye Services of New Jersey. Together, the team offers a full range of services including comprehensive eye exams, contact lens fitting, pediatric vision screening, custom progressives and specialty coatings, dry eye and allergy care, and on-site frame and lens repairs.

Patients also have access to a curated selection of more than 800 designer frames from leading brands, including the recently launched Ray-Ban Meta smart eyewear, alongside Aspex, Tura, Kenmark, Vera Wang, and others. An on-site lab allows for fast turnaround on repairs, adjustments, and many lens fittings.

Hampden Optical is located at 4900 Carlisle Pike, Mechanicsburg, PA 17050, and is open Monday through Friday from 9:00 AM to 5:00 PM. To schedule an eye exam or learn more, visit https://hampdenoptical.com or call 717-901-3939.

About Hampden Optical

Established in 1996, Hampden Optical is an independent eye care practice and designer eyewear destination serving Mechanicsburg, Harrisburg, Carlisle, and the wider Central Pennsylvania region. Owned by board-certified opticians Noelle Calzone and Michele Henry, the practice offers comprehensive eye exams, contact lens services, pediatric vision screening, dry eye and allergy care, custom progressives, and on-site frame and lens repairs, alongside a curated selection of more than 800 designer frames.

Learn more at https://hampdenoptical.com.

Media Contact
Company Name: Hampden Optical
Contact Person: Noelle Calzone
Email: Send Email
Phone: +17179013939
Address:4900 Carlisle Pike
City: Mechanicsburg
State: Pennsylvania (PA) 17050
Country: United States
Website: https://hampdenoptical.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Women-Owned Optical Practice: Noelle Calzone and Michele Henry Mark a New Era at Mechanicsburg’s Hampden Optical

Multiple System Atrophy Clinical Pipeline Intensifies with 20+ Industry Players Exploring Breakthrough Treatment Modalities | DelveInsight

DelveInsight’s “Multiple System Atrophy Pipeline Insight 2026” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in the Multiple System Atrophy pipeline landscape. It covers the Multiple System Atrophy Pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple System Atrophy Pipeline Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Multiple System Atrophy Pipeline? @ Multiple System Atrophy Pipeline Outlook Report

Key Takeaways from the Multiple System Atrophy Pipeline Report

  • On May 01, 2026- AstraZeneca initiated a phase I/II study will evaluate the safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9750 as monotherapy and in combination with saruparib in participants with metastatic prostate cancer. Additional combinations with other anticancer agents may be added via protocol amendment as separate modules. The study follows a modular design, allowing initial assessment of safety, tolerability, and preliminary efficacy across multiple treatment arms. Each Module has 2 parts: Part A (monotherapy dose escalation or combination dose finding) and Part B (monotherapy dose optimization and expansion or combination dose expansion). Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons to discontinue study intervention occur.
  • On April 30, 2026- Precision BioSciences Inc. conducted a Phase 1/2a trial is to evaluate the safety, tolerability, and preliminary efficacy of PBGENE-DMD in patients with DMD harboring mutations amenable to excision of exons 45-55. Given the limitations of existing therapeutic strategies, PBGENE-DMD represents a novel, innovative approach with the potential for a one-time, durable correction of the underlying genetic defect in the largest molecular subset of patients with DMD.
  • On April 29, 2026- Dasher Neuroscience Inc. initiated a Phase 2, double-blind, placebo-controlled, multi-center, Phase II, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and efficacy of Ya-101 in subjects with multiple system atrophy.
  • On April 28, 2026- PepGen Inc. announced a phase 2 study is to learn about the effects of an investigational medicine, PGN-EDODM1, to see how safe and tolerable multiple administrations of PGN-EDODM1 are for people with myotonic dystrophy type 1 (DM1) compared to placebo.
  • DelveInsight’s Multiple System Atrophy Pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Multiple System Atrophy treatment.
  • The leading Multiple System Atrophy Companies such as Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. andothers.
  • Promising Multiple System Atrophy Therapies such as TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.

Want to know which companies are leading innovation in Multiple System Atrophy? @ Multiple System Atrophy Clinical Trials Assessment

The Multiple System Atrophy Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Multiple System Atrophy Pipeline Report also highlights the unmet needs with respect to the Multiple System Atrophy.

Multiple System Atrophy Overview

Multiple system atrophy (MSA) is a rare disease, affecting potentially 15,000 to 50,000 Americans, including people of all racial groups. The cause of MSA is unknown. The vast majority of cases are sporadic, meaning they occur at random. Multiple system atrophy (MSA) is a progressive neurodegenerative disorder characterized by a combination of symptoms that affect both the central nervous system (which controls how a person moves), and the autonomic nervous system, which controls involuntary functions such as blood pressure or digestion.

Multiple System Atrophy Emerging Drugs Profile

  • Amlenetug: H. Lundbeck A/S

Amlenetug (also known as Lu AF82422), developed by H. Lundbeck A/S, is an investigational human monoclonal antibody designed to target neurodegenerative processes in multiple system atrophy. The drug specifically binds to extracellular α-synuclein, a pathological protein implicated in MSA, with the aim of preventing its uptake into cells and inhibiting the seeding and spread of toxic protein aggregates across the brain, additionally, through its active Fc region, it may enhance immune-mediated clearance of α-synuclein via microglial activity, thereby potentially slowing disease progression. The drug has received several important designations, including FDA Fast Track designation (2025), Orphan Drug Designation in the US, EU, and Japan, and SAKIGAKE designation in Japan, highlighting its potential to address a significant unmet medical need. Currently, amlenetug is in Phase III clinical development, being evaluated in the global MASCOT trial (NCT06706622), a randomized, double-blind, placebo-controlled study assessing its efficacy, safety, and tolerability in patients with MSA, with dosing administered via intravenous infusion approximately every four weeks.

  • ATH434: Alterity Therapeutics

ATH434, developed by Alterity Therapeutics, is an investigational oral small-molecule therapeutic designed to treat neurodegenerative diseases such as multiple system atrophy (MSA). The drug acts as an iron chaperone, targeting pathological processes by redistributing excess iron in the brain and inhibiting α-synuclein aggregation, which is a key driver of neurodegeneration in MSA, ATH434 aims to protect neurons and slow disease progression. ATH434 is being developed primarily for MSA, a rare and rapidly progressive neurodegenerative disorder with significant unmet medical need. The drug has received Orphan Drug Designation from the U.S. FDA and the European Commission, as well as FDA Fast Track designation, underscoring its potential clinical importance. Clinically, ATH434 has completed Phase II trials (ATH434-201/202), and based on positive data, the program is advancing toward Phase III development, positioning it as a late-stage asset in Alterity’s pipeline.

  • hOMSC300: Cytora Ltd.

hOMSC300, developed by Cytora Ltd., is an investigational allogeneic, off-the-shelf cell therapy, a unique stem cell population derived from the neural crest with properties of neural, mesenchymal, and regenerative cells. These cells exhibit a dual mechanism of action involving cell replacement and paracrine trophic effects, enabling neuroprotection, regeneration, and modulation of neuroinflammation, which are key pathological processes in neurodegenerative diseases. The therapy is being developed for multiple system atrophy (MSA), a rare and progressive neurodegenerative disorder affecting autonomic and motor functions, and aims to act as a disease-modifying treatment by slowing disease progression and preserving neuronal function. From a clinical development perspective, Cytora’s pipeline clearly indicates that hOMSC300 is currently in Phase I clinical studies for MSA, with ongoing trials evaluating safety and preliminary efficacy following intrathecal administration.

  • AB-1005: AskBio

AB-1005 is an investigational gene therapy developed by AskBio, a wholly owned subsidiary of Bayer AG. The therapy is based on an adeno-associated viral vector serotype 2 (AAV2) designed to deliver the gene encoding glial cell line-derived neurotrophic factor (GDNF) directly into the brain. Mechanistically, AB-1005 enables sustained local production of GDNF within targeted brain regions, which is intended to support the survival and function of dopaminergic neurons and enhance dopamine signaling, thereby addressing the underlying neurodegeneration. The therapy is currently being investigated in the Phase I stage of its development for the treatment of Multiple System Atrophy – parkinsonian type (MSA-P).

If you’re tracking ongoing Multiple System Atrophy Clinical trials, this press release is a must-read @ Multiple System Atrophy Treatment Drugs

The Multiple System Atrophy Pipeline report provides insights into:-

  • The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
  • Multiple System Atrophy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.

Multiple System Atrophy Companies

Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. andothers.

Multiple System Atrophy Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as,

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

Multiple System Atrophy Products have been categorized under various Molecule types such as,

  • Oligonucleotide
  • Peptide
  • Small molecule

From emerging drug candidates to competitive intelligence, the Multiple System Atrophy Pipeline Report @ Multiple System Atrophy Market Drivers and Barriers, and Future Perspectives

Scope of the Multiple System Atrophy Pipeline Report

  • Coverage- Global
  • Multiple System Atrophy Companies- Cytora Ltd., Alterity Therapeutics, H. Lundbeck A/S, AskBio, Corestemchemon, Inc., Tiziana Life Sciences Ltd., Kainos Medicine Inc., Ono Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., ProMIS Neurosciences, Inc., Ionis Pharmaceuticals, Inc., and Yoda Therapeutics Inc. and others.
  • Multiple System Atrophy Therapies- TEV-56286, YA-101, Foralumab Nasal, Verdiperstat, TAK-341, ATH434, Safinamide Methanesulfonate, Rasagiline Mesylate, ONO-2808, AZD3241, and others.
  • Multiple System Atrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple System Atrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay ahead in Healthcare Research – discover what’s next for the Multiple System Atrophy Treatment landscape in this detailed analysis @ Multiple System Atrophy Emerging Drugs and Major Players

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Multiple System Atrophy: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Multiple System Atrophy– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. NASP: Swedish Orphan Biovitrum A
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II/III)
  11. ABP-671: Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. PRX-115: Protalix Biotherapeutics Inc.
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug Name: Company Name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple System Atrophy Key Companies
  21. Multiple System Atrophy Key Products
  22. Multiple System Atrophy- Unmet Needs
  23. Multiple System Atrophy- Market Drivers and Barriers
  24. Multiple System Atrophy- Future Perspectives and Conclusion
  25. Multiple System Atrophy Analyst Views
  26. Multiple System Atrophy Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple System Atrophy Clinical Pipeline Intensifies with 20+ Industry Players Exploring Breakthrough Treatment Modalities | DelveInsight

Chronic Kidney Disease Drug Development Pipeline Expands as 75+ Companies Focus on Novel Mechanisms of Action | DelveInsight

DelveInsight’s, “Chronic Kidney Disease Pipeline Insight 2026” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Chronic Kidney Disease pipeline landscape. It covers the Chronic Kidney Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Chronic Kidney Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Chronic Kidney Disease Research @ https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight

Key Takeaways from the Chronic Kidney Disease Pipeline Report

  • On May 01, 2026- Medical College of Wisconsin initiated a study aimed to analyze the immunogenicity of nanovalent human papillomavirus vaccination (GARDASIL 9) in post-solid-organ transplant patients. The study duration is anticipated to be 36 months. The expected duration of subject participation is 24 months. Immunocompromised populations are at greater risk of HPV infection. Quadrivalent HPV vaccination has been performed and lower titers of antibodies have been compared to published date in non-immunocompromised population (controls). The HPV9 vaccination titers have not been measured in the immunocompromised population to date.
  • On May 01, 2026- Vifor Fresenius Medical Care Renal Pharma conducted a study is to evaluate the safety and tolerability, as assessed by incidence of AEs, of 0.5 μg/kg IV difelikefalin in adolescent participants on HD (3 times weekly) with moderate-to-severe pruritus over 12 weeks. Additionally, difelikefalin plasma concentrations (Cmax and Ctrough) after multiple administrations will be evaluated at a few selected time points and the efficacy of difelikefalin in improving itching and health-related QoL will be investigated as exploratory.
  • DelveInsight’s Chronic Kidney Disease pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Chronic Kidney Disease treatment.
  • The leading Chronic Kidney Disease Companies such as AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
  • Promising Chronic Kidney Disease Pipeline Therapies such as roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.

Stay informed about the cutting-edge advancements in Chronic Kidney Disease treatments @ Chronic Kidney Disease Clinical Trials Assessment

Chronic Kidney Disease Overview

Chronic kidney disease (CKD) is characterized by the presence of kidney damage or an estimated glomerular filtration rate (eGFR) of less than 60 mL/min/1.73 m², persisting for 3 months or more. CKD involves a progressive loss of kidney function, often leading to the need for renal replacement therapy, such as dialysis or transplantation. It is a condition in which kidneys are damaged and cannot filter blood. As a result, extra fluid and waste from the blood remain in the body, potentially leading to various health issues like heart disease and stroke. Chronic Kidney Disease has various levels of seriousness. It usually gets worse with time though treatment has been shown to slow progression. If left untreated, CKD can progress to kidney failure and early cardiovascular disease.

Chronic Kidney Disease Emerging Drugs Profile

  • Baxdrostat : AstraZeneca

Baxdrostat, a highly potent inhibitor of aldosterone synthase, exhibits greater selectivity for aldosterone synthase compared to existing ASIs. Initial studies in cynomolgus monkeys demonstrated its ability to decrease aldosterone production, prompting further investigation in humans. The mechanism of action of baxdrostat involves inhibiting the enzyme aldosterone synthase, which is responsible for the final step in aldosterone biosynthesis. By selectively blocking this enzyme, baxdrostat reduces aldosterone levels, leading to decreased sodium reabsorption and fluid retention, ultimately lowering blood pressure. The drug is currently being evaluated in the Phase III stage of development for the treatment of patients with CKD.

  • Ziltivekimab: Novo Nordisk

Ziltivekimab is a proprietary anti-interleukin-6 ligand monoclonal antibody (anti-IL6 mAb), targeting residual inflammatory cardiovascular risk in patients living with advanced chronic kidney disease (CKD). Ziltivekimab is being developed a therapy intended to reduce the risk of major cardiovascular adverse events in chronic kidney disease (CKD) patients with atherosclerotic cardiovascular disease (ASCVD) and inflammation. Patients who are diagnosed with moderate to severe CKD and have ASCVD and inflammation are at risk for an adverse cardiovascular event at a high rate and there are no approved therapies to prevent this risk. The proinflammatory cytokine, interleukin-6 (IL-6) has been shown to be an independent, causal factor of ASCVD with evidence generated from human genetic studies and preclinical studies. The drug is being evaluated in the Phase III stage of development to treat patients with moderate to severe chronic kidney disease.

  • BI-685509: Boehringer Ingelheim

BI 685509 is a novel small soluble guanylate cyclase (sGC) molecule activator that exhibits an in vitro profile consistent with that of an sGC activator. BI 685509 reduced proteinuria and glomerulosclerosis in the ZSF1 rat, a model of diabetic kidney disease (DKD), and reduced tubulointerstitial fibrosis in a 7-day unilateral ureteral obstruction model in rats. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Chronic Kidney Disease.

  • PXL770: Poxel SA

PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). Currently, the drug is in the Phase I stage of Clinical trial evaluation for the treatment of Autosomal Dominant Polycystic Kidney Disease.

  • RGLS8429: Regulus Therapeutics

RGLS8429 is a novel, next-generation oligonucleotide for the treatment of ADPKD designed to inhibit miR-17 and to preferentially target the kidney. Administration of RGLS8429 has shown robust data in preclinical models, where clear improvements in kidney function, size, and other measures of disease severity have been demonstrated along with a superior pharmacologic profile in preclinical studies compared to Regulus’ first-generation compound. Currently, the drug is in Phase I for the treatment of Chronic Kidney Disease.

The Chronic Kidney Disease Pipeline Report Provides Insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Chronic Kidney Disease with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease Treatment.
  • Chronic Kidney Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Chronic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Chronic Kidney Disease market

Learn more about Chronic Kidney Disease Drugs opportunities in our groundbreaking Chronic Kidney Disease Research and development projects @ Chronic Kidney Disease Unmet Needs

Chronic Kidney Disease Companies

AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.

Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

Chronic Kidney Disease Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Discover the latest advancements in Chronic Kidney Disease treatment by visiting our website @ Chronic Kidney Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Chronic Kidney Disease Pipeline Report

  • Coverage- Global
  • Chronic Kidney Disease Companies- AstraZeneca, Eli Lilly and Company, Shandong Suncadia Medicine, Boehringer Ingelheim, AdAlta, Alebund Pharmaceuticals, SCOHIA PHARMA, DiaMedica Therapeutics, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Regulus Therapeutics, UnicoCell Biomed, Regeneron Pharmaceuticals and others.
  • Chronic Kidney Disease Pipeline Therapies- Roxadustat, Monofer®, AZD5718, Dapagliflozin 10 mg, MEDI8367, AST-120, and others.
  • Chronic Kidney Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Chronic Kidney Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Read the full details of Chronic Kidney Disease Pipeline on our website @ Chronic Kidney Disease Emerging Drugs and Companies

Table of Content

  1. Introduction
  2. Executive Summary
  3. Chronic Kidney Disease: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Chronic Kidney Disease– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Baxdrostat: AstraZeneca
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. BI-685509: Boehringer Ingelheim
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RGLS8429: Regulus Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Chronic Kidney Disease Key Companies
  21. Chronic Kidney Disease Key Products
  22. Chronic Kidney Disease- Unmet Needs
  23. Chronic Kidney Disease- Market Drivers and Barriers
  24. Chronic Kidney Disease- Future Perspectives and Conclusion
  25. Chronic Kidney Disease Analyst Views
  26. Chronic Kidney Disease Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chronic Kidney Disease Drug Development Pipeline Expands as 75+ Companies Focus on Novel Mechanisms of Action | DelveInsight

Obesity Clinical Trial Ecosystem Strengthens with 80+ Companies Driving Next-Gen Oncology Innovations | DelveInsight

DelveInsight’s “Obesity Pipeline Insight 2026” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the obesity pipeline landscape. It covers the Obesity pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Obesity therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Obesity pipeline products in this space.

Download DelveInsight’s comprehensive Obesity Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/obesity-pipeline-insight

Key Takeaways from the Obesity Pipeline Report

  • On May 01, 2026- Boehringer Ingelheim initiated a phase 3 study is open to adults who are at least 18 years old and have a body mass index (BMI) of 27 kg/m2 or more. People can take part if they have cardiovascular or chronic kidney disease. People who have at least 2 health problems related to their weight or risks of cardiovascular disease can participate. Participants must have previously tried to lose weight by changing their diet.
  • DelveInsight’s Obesity pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Obesity treatment.
  • The leading Obesity Companies such as Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
  • Promising Obesity Therapies such as APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.

Access DelveInsight’s in-depth pipeline Analysis for a closer look at promising breakthroughs @ Obesity Clinical Trials and Studies

The Obesity Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Obesity Pipeline Report also highlights the unmet needs with respect to the Obesity.

Obesity Overview

Obesity is the excessive or abnormal accumulation of fat or adipose tissue in the body that impairs health via its association with the risk of development of diabetes mellitus, cardiovascular disease, hypertension, and hyperlipidemia. It is a significant public health epidemic which has progressively worsened over the past 50 years.

Obesity Emerging Drugs

  • Survodutide: Zealand Pharma

Survodutide (BI 456906) is a long-acting glucagon/GLP-1 receptor dual agonist for once-weekly subcutaneous administration that activates two key gut hormone receptors simultaneously and may offer better efficacy than current single-hormone receptor agonist treatments. Survodutide is targeting the treatment of obesity and nonalcoholic steatohepatitis (NASH). Boehringer Ingelheim is advancing survodutide into three global Phase III trials in people living with overweight or obesity.

  • Ecnoglutide: Sciwind Biosciences

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for NASH. Ecnoglutide (XW003) is a novel, cAMP signaling biased, long-acting GLP-1 analogue optimized for improved biological activity, cost-effective manufacturing, and once weekly dosing. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Obesity.

  • CT-868: Carmot Therapeutics

CT-868 is a dual GLP-1 and GIP receptor modulator with a unique pharmacological profile optimized for improved tolerability at the GLP-1 receptor. The combined action of GLP-1 and GIP results in greater body weight loss and glucose control. CT-868 is dosed once daily to maximize efficacy and tolerability. CT-868 dual agonist candidate was discovered using the chemotype evolution technology as a peptide-small molecule hybrid compound, able to mimic the native GLP-1 hormone. In the Phase I trial, CT-868 demonstrated compelling pharmacodynamic activity across several clinical measures in overweight and obese healthy individuals a safe and generally well-tolerated profile. Carmot Therapeutics is now expanding the observations in overweight and obese patients with type 2 diabetes to demonstrate CT-868’s effects on glycemic control, weight loss, and tolerability. Currently, the drug is in the Phase II stage of development to treat obesity.

  • DD01: D&D Pharmatech

DD01 is a proprietary, imbalanced dual agonist of GLP-1 and glucagon receptors with a half-life of 11 days in non-human primates. DD01 is being developed as a potential disease-modifying agent for obesity and liver fatty disease. Treatment with DD01 caused weight loss, reduced liver fat, and improved glucose tolerance in preclinical obesity, diabetes, and fatty liver models. In preclinical models of diabetes and nonalcoholic fatty liver disease (NAFLD), DD01 could reduce weight and blood sugar and improve insulin sensitivity and lipid and fat metabolism, which could ameliorate NASH. DD01 demonstrated greater efficacy in preclinical models than semaglutide, an approved GLP-1R receptor agonist; from a mechanical perspective, the effect of DD01 persisted after cessation of treatment. It is currently being evaluated in Phase I clinical trial to investigate the safety, tolerability, PK, and PD of DD01 administered by subcutaneous (SC) injection in overweight/obese subjects with type 2 diabetes mellitus and nonalcoholic fatty liver disease (NAFLD).

Explore DelveInsight’s expert-driven report today! @ Obesity Unmet Needs

The Obesity pipeline report provides insights into

  • The report provides detailed insights about companies that are developing therapies for the treatment of Obesity with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Obesity Treatment.
  • Obesity Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Obesity Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Obesity market.

Obesity Companies

Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.

Obesity pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Obesity Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical

Obesity Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

Download DelveInsight’s latest report to gain strategic insights into upcoming Obesity Therapies @ Obesity Market Drivers and Barriers, and Future Perspectives

Scope of the Obesity Pipeline Report

  • Coverage- Global
  • Obesity Companies- Zealand Pharma, Sciwind Biosciences, Genexine, Sirnaomics, Sparrow Pharmaceuticals, Shionogi, Regor Pharmaceuticals, Innovent Biologics, Pfizer, NodThera Limited, Boehringer Ingelheim, Fractyl Health, TransThera, Clearmind Medicine, PegBio, Biolingus, and others.
  • Obesity Therapies- APHD-012, Bimagrumab, Semaglutide, CT-868, GLY-200, Bremelanotide, and others.
  • Obesity Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Obesity Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find out in DelveInsight’s exclusive Obesity Pipeline Report @ Obesity Emerging Drugs and Major Companies

Table of Contents

  1. Introduction
  2. Executive Summary
  3. Obesity Overview
  4. Obesity Pipeline Therapeutics
  5. Obesity Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Survodutide: Zealand Pharma
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. CT-868: Carmot Therapeutics
  11. Drug profiles in the detailed report…..
  12. Early Stage Products (Phase I)
  13. DD01: D&D Pharmatech
  14. Drug profiles in the detailed report…..
  15. Preclinical and Discovery Stage Products
  16. Drug name: Company name
  17. Drug profiles in the detailed report…..
  18. Inactive Obesity Products
  19. Obesity Key Companies
  20. Obesity Key Products
  21. Obesity Unmet Needs
  22. Obesity Market Drivers
  23. Obesity Market Barriers
  24. Obesity: Future Perspectives and Conclusion
  25. Obesity Analyst Views
  26. Obesity Key Companies
  27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/obesity-pipeline-insight

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Obesity Clinical Trial Ecosystem Strengthens with 80+ Companies Driving Next-Gen Oncology Innovations | DelveInsight